• Discover real-world clinician and patient experiences with clonoSEQ MRD testing

    View cases, videos, patient perspectives and
    more which illustrate how clonoSEQ MRD testing
    can be used as a decision-making tool.

    Real-world Experience Hub
  • clonoSEQ
    MRD Monitoring

    View the technical summary
  • A patient with CLL tells his MRD story

    Lee shares his journey as a patient with chronic lymphocytic leukemia (CLL) and how MRD testing has given him peace of mind.

    Watch Lee's Story
  • A myeloma patient's perspective on MRD

    Watch Tim’s story
  • Adaptive Assist

    Learn More

What is MRD?

Even if you are responding well to treatment or are in remission, a small number of cancer cells can remain in your body, and may cause your disease to return. This is called measurable (or minimal) residual disease, also known as MRD.

Barcodegif Fdd56e3f

With MRD testing, you and your doctor have a personalized way to track—and talk about—your body’s individual response to treatment.


News and Updates

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today received clearance from the U.S. Food and Drug Administration (FDA) for its clonoSEQ® Assay to detect and monitor minimal residual disease (MRD) in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL).

View Press Release

May, 2020

Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing.

View Press Release

April, 2020

Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19.

View Press Release

This page is intended for use by healthcare professionals of the United States.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.

Contact Us

Make an inquiry to learn more about our products.